HIV exposure

Journal of Gynecologic Surgery

Volumn 12, Issue 3, 1996, Pages 223-224

  Osborne, Newton G ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; RITONAVIR; ZIDOVUDINE;

ARTICLE; DRUG EFFICACY; DRUG RESEARCH; GYNECOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PRIORITY JOURNAL; VIRUS INHIBITION;

EID: 0029861705     PISSN: 10424067     EISSN: None     Source Type: Journal    
DOI: 10.1089/gyn.1996.12.223     Document Type: Article

References (7)

1. Karon JM, Rosenberg PS, McQuillan G, et al. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 1996;276:126.
2. CDC. Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39(no. RR-I).
3. CDC. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468.
4. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173.
5. Schapiro JM, Winters MA, Stewart F, et al. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients. Ann Intern Med 1996;124:1039.
6. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995;269:696.
7. Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis 1996;173:355.